Steve Hitchcock, Ph.D. is the global head of research at Takeda Pharmaceuticals, where he is responsible for the global research organization at Takeda across the three therapeutic areas of neuroscience, oncology and GI from pre-clinical to clinical early proof-of-concept. Dr. Hitchcock joined Takeda as part of their acquisition of Envoy Therapeutics, where he was the chief scientist and senior vice president of drug discovery. Prior to Takeda, Dr. Hitchcock served in senior leadership positions in the research organizations at both Eli Lilly and Amgen. In addition, Dr. Hitchcock served as an adjunct professor in the department of molecular therapeutics at Scripps Florida, a division of The Scripps Research Institute. He completed a NATO postdoctoral fellowship at Yale University and received a Ph.D. in organic chemistry from The University of Nottingham (U.K.).